Publications by authors named "R Sansores"
Background: COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City.
View Article and Find Full Text PDFUnlabelled: Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by local and systemic inflammation independently of the risk factor; during the exacerbations, such inflammation is accentuated and amplified. A practical inflammatory marker and one with an applicable predictive value in the follow-up has been sought. FeNO has shown an excellent performance in that respect within the context of asthma and has also been studied in tobacco-smoke COPD (COPD-TS).
View Article and Find Full Text PDFsRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant.
Heliyon
April 2024
Article Synopsis
- The study investigates the relationship between certain genetic variants (rs2071288, rs3134940, rs184003, and rs2070600) and soluble-RAGE levels in patients with chronic obstructive pulmonary disease (COPD) related to biomass-burning smoke (BBS) and tobacco smoking.
- Researchers analyzed 2189 subjects divided into four groups to determine if these variants and RAGE levels were linked to COPD, but found no strong associations, except a marginal one for rs3134940 with COPD-BBS.
- The findings revealed that sRAGE plasma and sputum levels were lower in COPD patients compared to non-COPD individuals, with rs3134940 influencing these levels, but the genetic variants themselves did
Introduction: One of the major concerns with post-acute sequelae of COVID-19 (PASC) is the development of pulmonary fibrosis, for which no approved pharmacological treatment exists. Therefore, the primary aim of this open-label study was to evaluate the safety and the potential clinical efficacy of a prolonged-release pirfenidone formulation (PR-PFD) in patients having PASC-pulmonary fibrosis.
Methods: Patients with PASC-pulmonary fibrosis received PR-PFD 1800 mg/day (1200 mg in the morning after breakfast and 600 mg in the evening after dinner) for three months.
Article Synopsis
- Lung microbiome dysbiosis can lead to immune system imbalances and lung inflammation, prompting a study comparing the lung bacteriome and cytokine profiles of women with normal lung function exposed to either tobacco smoke or biomass-burning smoke.
- The research involved analyzing induced sputum from two groups: women exposed to biomass-burning smoke and current smokers, focusing on the composition of bacteria and measurement of cytokine levels.
- Results indicated that current smokers had a higher concentration of IL-1β and a different bacteriome composition but did not show statistically significant differences in specific bacteria after adjustments, highlighting potential negative effects of smoking on lung health compared to biomass exposure.